Answers are grounded in this paper and cite their sources.
Chikungunya virus (CHIKV) is a mosquito-borne alphavirus that can cause fever, severe joint pain and neurological complications. Although vaccines against CHIKV are available in some regions there is still a need for additional vaccine strategies. In this study we used a computational immunoinformatic approach to design a multi-epitope vaccine candidate from the CHIKV structural polyprotein. B-cell epitopes and MHC-I and MHC-II epitopes were identified and screened for antigenicity, immunogenicity, allergenicity and toxicity. The selected epitopes were joined using suitable linkers and a 50 S ribosomal L7/L12 protein was added as an adjuvant. The final construct showed favourable predicted physicochemical and structural properties with an antigenicity score of 0.524. It was also predicted to be non-allergenic and non-toxic. Molecular docking showed favourable interaction with TLR-9, and a 200 ns molecular dynamics simulation indicated stability of the modelled vaccine–receptor complex. Immune simulation predicted both humoral and cellular immune responses. Overall, this study provides a computationally designed CHIKV multi-epitope vaccine candidate that can be considered for further experimental evaluation. In vitro and in vivo studies are needed to confirm its safety, immunogenicity and protective efficacy.
No takes yet. Share an insight, caveat, or question.
Hayat et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: